Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Taxanes in combined-modality therapy for solid tumors.

H Choy1

  • 1Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Oncology (Williston Park, N.Y.)
|November 7, 1999
PubMed
Summary

Taxanes like paclitaxel and docetaxel are effective antimitotic drugs for solid tumors. Combining taxanes with radiation therapy shows promise across various cancers, particularly during the radiosensitive G2/M cell cycle phase.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Improving outcomes in the treatment of locally-advanced NSCLC with gemcitabine.

Lung cancer (Amsterdam, Netherlands)·2005
Same author

A phase I trial of outpatient weekly irinotecan/carboplatin and concurrent radiation for stage III unresectable non small-cell lung cancer: a Vanderbilt-Ingram Cancer Center Affiliate Network Trial.

Clinical lung cancer·2004
Same author

Topoisomerase I inhibitors in the combined modality therapy of lung cancer.

Clinical lung cancer·2004
Same author

A phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non small-cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial.

Clinical lung cancer·2004
Same author

Management of unresectable non-small cell carcinoma of the lung (NSCLC).

Lung cancer (Amsterdam, Netherlands)·2004

Area of Science:

  • Oncology
  • Pharmacology
  • Radiation Oncology

Background:

  • Taxanes (paclitaxel, docetaxel) are novel antimitotic agents investigated for solid tumors.
  • These agents exhibit significant activity as monotherapy and in combination regimens.
  • Taxanes induce cell cycle arrest at the G2/M phase, a highly radiosensitive period.

Purpose of the Study:

  • To review recent clinical trials evaluating taxane-based chemoradiation therapy for solid tumors.
  • To highlight the efficacy of paclitaxel and docetaxel in combination with radiation therapy.
  • To summarize findings across various cancer types treated with taxane-radiation combinations.

Main Methods:

  • Review of recent clinical trials involving taxanes (paclitaxel, docetaxel) and radiation therapy.
  • Analysis of studies across multiple solid tumor types.
  • Focus on chemoradiation therapy regimens.

Main Results:

  • Paclitaxel-based chemoradiation has been extensively studied in non-small-cell lung cancer, head and neck cancers, esophageal cancer, brain tumors, pancreatic/gastric tumors, and locally advanced breast cancer.
  • Docetaxel plus radiation therapy has been assessed in fewer clinical trials for these tumor types.
  • Taxanes demonstrate significant activity when combined with radiation therapy.

Conclusions:

  • Taxanes are effective antimitotic agents with demonstrated activity in solid tumors.
  • Combining taxanes with radiation therapy is a promising strategy for various solid malignancies.
  • Further investigation into docetaxel-based chemoradiation may be warranted.

Related Experiment Videos